If Roche is successful in securing FDA approval, use of pertuzumab together with trastuzumab (also developed by Genentech's parent company, Roche) could help the drug maker hold on to some of its oncology market dominance in the face of growing competition from anticancer biosimilars.
Genentech, a member of the Roche Group, has announced that it has been granted FDA priority review for its supplemental biologics license application (sBLA) for pertuzumab (Perjeta), together with trastuzumab (Herceptin) and chemotherapy, for adjuvant treatment of HER2-positive early breast cancer (EBC). The FDA is expected to issue a regulatory decision by January 28, 2018.
The sBLA relies on data from the phase 3 APHINITY study. The international, randomized, double-blind, placebo-controlled, 2-arm study evaluated the efficacy and safety of trastuzumab and chemotherapy combined with either pertuzumab or placebo, as adjuvant treatment in 4805 patients who had operable HER2-positive EBC. The study’s primary endpoint was invasive disease-free survival (iDFS), which the study defined as the time that a patient lives without the return of invasive breast cancer at any site and without death from any cause after adjuvant treatment.
The rate of iDFS at 3 years was 94.1% in the pertuzumab, trastuzumab, and chemotherapy arm, and 93.2% in the trastuzumab, chemotherapy, and placebo arm. Estimated iDFS at 4 years, based upon data available to date, was 92.3% and 90.6% in the 2 arms, respectively.
The fact that the FDA has granted a priority review of the drug—a review designation available only to medicines that the agency has determined to have the potential to provide significant improvements in treatment, prevention, or diagnosis of a disease—suggests that the agency may see the APHINITY study’s results as more impressive than investors did. When results of the trial were announced in June, Roche’s stock sank by 5.2% on concerns that the high cost of pertuzumab therapy relative to the improvements that it offered would keep the drug from being widely used in low-risk patients.
An analysis published in the Journal of Clinical Oncology, which assessed cost effectiveness of pertuzumab plus trastuzumab in the earlier CLEOPATRA study (a study that assessed pertuzumab and trastuzumab in metastatic breast cancer), concluded that use of the combination was unlikely to be cost effective, at least in treating metastatic breast cancer, in the United Sates.
If Roche is successful in securing FDA approval, use of pertuzumab together with trastuzumab (also developed by Roche) could help the drug maker hold on to some of its oncology market dominance in the face of growing competition from anticancer biosimilars. Additionally, some analysts have said that the fact that pertuzumab would extend the duration of a patient’s treatment will contribute to higher sales overall sales for Roche.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.